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inverse relationship between adiponectin and body composition in HF
patients require further evaluation. Furthermore,while previous studies
have attributed this phenomenon to disease-related atrophy and
cachexia, we show that even in patients with average physique,
adiponectin levels remain elevated in patients with diagnosed HF.
Future studies should seek correlations between prognosis and body
composition, in order to determine if adiponectin could potentially be
used as a prognosticator among this patient population.
This study was funded by VA Merit Award F4726R.
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The role of natriuretic peptides (NPs) as independent predictors of
cardiovascular events, hospitalization and death [1,2] in older adults
has been already demonstrated and is related to their hemodynamic
actions (natriuresis, diuresis, vasodilatation and inhibition of the renin–
angiotensin–aldosterone system) [3]. Besides these, NPs have metabolic
and lipolytic actions [4]. Interestingly, lower plasmatic NPs levels are
found in overweight and obese subjects when compared to lean ones in
several clinical settings [4], which raise doubts concerning the usefulness
of NPs as prognostic biomarkers in overweight/obese subjects. We
aimed to investigatewhether the ability of B-type NP (BNP) to predict
11-year mortality risk in community-dwelling elderly of the Bambuí
(Brazil) Cohort Studyof Aging (BHAS) differed in relation to overweight/
obesity and abdominal obesity status.
The BHAS, a cohort study of elderly residents in the Bambuí City
(Minas Gerais, southeast of Brazil) is described in detail elsewhere [5],
and was approved by the ethics board of the Fundação Oswaldo Cruz,
Belo Horizonte, Brazil. An informed consent form was obtained from all
participants. The authors of this manuscript have certiﬁed that they
comply with the Principles of Ethical Publishing.
The outcome of the present analysis was overall death from
baseline (1997) to 2007. Anthropometricmeasures (AM) assessment,
B-type natriuretic (BNP), Trypanossoma cruzi tests and deﬁnitions of
other measurements performed were detailed previously [5]. We
classiﬁed individuals in subgroups with (BMI ≥ 25 kg/m2) or with-
out (BMI b 25 kg/m2) overweight/obesity and with (WC ≥ 88 cm
for women and ≥102 cm for men) or without abdominal obesity
(WC b 88 cm for women and b102 cm for men).
To deal with missing values, we performed multiple imputation [6].
This procedure generated ﬁve complete datasets, which were used to
estimate crude and adjusted hazard ratios (HR) for death by Cox
regression models. BNP was subsequently added to models adjusted for
BMI (continuous and quadratic term) or WC (continuous), age
(continuous), gender, Chagas disease (no, yes), current smoking (no,
yes), diabetes (no, yes), total cholesterol (continuous), systolic blood
pressure (continuous), major ECG abnormalities (no, yes), log-
Table 2
Differences in plasma serum concentrations between HF and control subjects.
HF Controls Signiﬁcance
Adiponectin 23.5 ± 15.9 16.7 ± 8.2 b0.05
NT-proBNP 1522.2 ± 1827.9 168.2 ± 398.5 b0.001
Leptin 12.4 ± 15.4 10.5 ± 11.4 NS
Insulin 37.0 ± 39.8 26.1 ± 31.8 NS
Glucose 120.2 ± 63 100.4 ± 23.5 NS
☆ All authors take responsibility for all aspects of the reliability and freedom frombias of
the data presented and their discussed interpretation.
⁎ Corresponding author at: Rua Rogério Fajardo, 180/401, CEP 30310–450, Belo Horizonte,
MG, Brazil. Tel.: +55 31 325161098; fax: +55 31 32233328.
E-mail address: abeleigoli@gmail.com (A.M. Beleigoli).
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transformed serum creatinine level (continuous), physical activity (no,
yes), education (never studied (low), b4 school years (intermediate),
≥4 school years (high)), monthly household income (1–4 (low), 4–10
(intermediate), ≥10 minimum wage (high)). Additionally, we added
product terms of interaction between BNP and BMI/WC to verify the
effect modiﬁcation of BMI and WC on the association between BNP
and death.
The agreement between observed and predicted events (calibration)
at the end of the follow-up (t= 11 years) was assessed for eachmodel by
amodiﬁed Hosmer–Lemeshow chi-square statistic with nine df, inwhich
the observed incidence of the outcomewas compared to the probabilities
of events predicted by Cox models across ten groups yielded by the
deciles of the predicted probabilities [7]. The incremental improvement of
BNP to the ability ofmodels in predicting deathwas assessed bymeans of
discrimination, net reclassiﬁcation improvement (NRI) and integrated
discriminative improvement (IDI) for the whole population and for the
subgroups with and without obesity or abdominal obesity. Discrimina-
tion (i.e., ability of themodels to separate between individuals who had
or did not have the event) was assessed by Harrell's C-statistics at
t = 11 years, and compared byDe Longet al. test for themodelswithout
andwith BNP [8]. The impact of the addition of BNP tomodel the correct
movement of cases across categories of risk for events and non-events
was evaluated by NRI [9]. Categories of risk were based on the tertiles of
the probabilities estimated by the model without BNP (b0.22, 0.22 to
0.43, ≥0.43). Differences in integrated sensitivity and integrated one
minus speciﬁcity between the new and the model without BNP were
tested by IDI [9].
Of the 1606 participants enrolled at baseline, 1450 (90.3%) had BMI,
and 1454 (90.5%) hadWCmeasurements, respectively. Mean follow-up
time was 8.8 years, which led to 12, 971 person-years of follow-up.
Deaths occurred among 523 participants along the follow-up time.
Median BMI was 21.7 kg/m2 (IQR 19.8–23.4) and 28.1 kg/m2 (IQR 26.5–
30.3) in thesubgroupswithoutandwithoverweight/obesity, respectively.
BNP levels were higher in the subgroup without (90 pg/mL, IQR 50–163)
than with (74 pg/mL, IQR 40–137; p b 0.001) overweight/obesity. Other
characteristics of the participants at baseline, according to overweight/
obesity and abdominal obesity are depicted in Table 1. BNP predicted
mortality in models with BMI (HR 1.24; 95% CI 1.10–1.39) and WC (HR
1.22; 95% CI 1.09–1.38). Neither BMI norWCmodiﬁed the effect of BNP on
mortality (p for interaction= 0.53 and 0.88, respectively). All models
were well-calibrated (p N 0.05) and the addition of BNP yielded either a
non signiﬁcant or a modest improvement to the models with traditional
risk factors (Table 2).
Keeping with previous studies, we found an independent prognostic
value of BNP for death in older adults [1,2]. Regarding the ﬁndings of the
lack of inﬂuence of obesity on the association between BNP and death,
results in agreement [10,11] and contrary [12] to ours have been
previously reported in diverse clinical settings.
The investigation of the incremental value of BNP as a prognostic
marker, and not only of its statistical signiﬁcance as a determinant of
death adds contribution to the investigation of a critical issue to clinical
application of BNP as a prognostic biomarker in community-dwelling
elderly. The use of bothWC and BMI asmarkers of obesity decreases the
probability that the results are related to misclassiﬁcation of obesity by
Table 1
Baseline characteristics according to overweight/obesity and abdominal obesity groups.
Characteristics Overweight/obesity⁎ p
value†
Abdominal obesity⁎ p
value†No
(747; 51.5%)
Yes
(703; 48.5%)
No
(815; 56.1%)
Yes
(639; 44.0%)
Age, mean (SD) 70 68 b0.001 69 69 0.181
(8) (7) (7) (7)
Female sex, n (%) 395 484 b0.001 314 566 b0.001
(52.9) (68.8) (38.5) (88.6)
Chagas disease, n (%) 320 216 b0.001 309 229 b0.001
(43.8) (31.3) (38.9) (36.4)
Diabetes, n (%) 69 138 b0.001 79 127 b0.001
(9.5) (20.0) (10.0) (20.2)
Systolic blood pressure, mean (SD) 136 139 0.003 136 139 0.025
(24) (21) (23) (22)
Cholesterol, mean (SD) 229 238 0.003 227 242 b0.001
(49) (49) (48) (49)
Creatinine, median (IQR) 0.87 0.84 0.019 0.90 0.80 b0.001
(0.76–1.00) (0.74–0.98) (0.78–1.04) (0.72–0.92)
Major ECG abnormalities, n (%) 328 246 b0.001 332 245 0.275
(44.9) (35.7) (41.8) (39.0)
Smoking, n (%) 183 68 b0.001 203 50 0.332
(25.1) (9.9) (25.6) (7.9)
Physically active‡, n (%) 140 190 b0.001 169 143 0.440
(16.7) (24.8) (20.7) (22.4)
Household income§, n (%)
Low/Intermediate 697 623 b0.001 743 580
(93.9) (89.4) (92.2) (91.1)
High 45 74 63 57
(6.1) (10.6) (7.8) (8.9)
Education||, n (%)
Low/Intermediate 791 600 b0.001 735 558 0.041
(92.5) (85.3) (95.3) (87.3)
High 56 103 79 81
(7.5) (14.7) (9.7) (12.7)
⁎Overweight/obesity: bodymass index≥25 kg/m2; abdominal obesity:waist circumference≥88 cm forwomen and 102 cm formen† P value: Student's t test, Pearson's chi square test and
the Mann–Whitney test for differences between means, frequencies and medians, respectively between the groups with and without obesity and abdominal obesity ‡Leisure physical
activity (walking or any other physical exercise) for at least 20–30 min, ≥3–5 times/week § Monthly household income in minimumwages (lower category 1–4, intermediate category
4–10, higher category ≥10) || Education: lower category-never studied, intermediate category - b4 school years, higher category - ≥4 school years) |.
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BMI in the elderly. However, we might have lacked power to ﬁnd an
effect modiﬁcation of BMI andWC on the association between BNP and
death, and to extend our conclusions to the subgroup of subjects with
BMI ≥ 40 kg/m2 (n= 12; 1.1%).
In conclusion, BNP was associated with increased mortality among
elderly with and without overall or abdominal obesity. Despite being an
independent predictor of death, the rational use of BNP in the
elderly must take into account that the biomarker led only to a modest
incremental improvement in the prediction of long-term death
compared to traditional cardiovascular, clinical and socioeconomic risk
factors regardless of overall or abdominal obesity status.
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Table 2
Changes in discrimination (C-statistics), net reclassiﬁcation improvement (NRI) and
integrated discrimination improvement (IDI) after addition of BNP to the models.
Model Model without BNP* Model with BNP†
All subjects-model with BMI
C-statistic 0.80 (0.76–0.81) 0.80 (0.79–0.82)
p value‡ 0.25
NRI § ———— 0.01
p value 0.58
IDI || ———— 0.01
p value b0.001
Participants with overweight/obesity-models with BMI
C-statistic 0.78 (0.76–0.79) 0.78 (0.76–0.80)
p value‡ 0.57
NRI § ———— 0.07
p value 0.02
IDI || ———— 0.02
p value b0.001
Participants without overweight/obesity-models with BMI
C-statistics 0.81 (0.77–0.81) 0.82 (0.80–0.84)
p value ‡ 0.10
NRI § ———— 0.01
p value 0.51
IDI || ———— 0.01
p value b0.001
All subjects-model with WC
C-statistics 0.80 (0.77–0.81) 0.80 (0.79–0.81)
p value‡ 0.25
NRI § ———— 0.12
p value b0.001
IDI || ———— 0.05
p value b0.001
Participants with abdominal obesity-model with WC
C-statistics 0.77 (0.73–0.80) 0.77 (0.74–0.78)
p value‡ 0.93
NRI § ———— 0.02
p value 0.42
IDI || ———— 0.01
p value b0.001
Participants without abdominal obesity-model with WC
C-statistics 0.80 (0.77–0.83) 0.82 (0.80–0.84)
p value ‡ 0.02
NRI § ———— 0.02
p value 0.39
IDI || ———— 0.01
p value b0.001
* Model without BNP: BMI (continuous and quadratic term) or WC (continuous), age
(continuous), gender, Chagas disease (no, yes), current smoking (no, yes), diabetes (no,
yes), total cholesterol (continuous), major ECG abnormalities (no, yes), log-
transformed serum creatinine level (continuous), physical activity (no, yes), education
(never studied (low), b4 school years (intermediate), ≥4 school years (high)), monthly
household income (1–4 (low), 4–10 (intermediate), ≥10 minimumwage (high)).
† Model with BNP: Model without BNP plus log-BNP (continuous).
‡ p value refers to comparison of c-statistics between the models without and with BNP by De
Long et al. method.
§ NRI quantiﬁes the correct movement across categories of risk yielded by the addition of BNP
to the model for events and non-events. The categories of risk were established according to
the quartiles of the predicted probabilities of the model without BNP with BMI (b0.22, 0.22 to
0.43, ≥0.43).
|| IDI refers to differences in integrated sensitivity and one minus speciﬁcity between the
models with and without BNP.
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